Search Results - "KARPF, D. M."

In vivo clearance and metabolism of recombinant activated factor VII (rFVIIa) and its complexes with plasma protease inhibitors in the liver by Seested, T, Appa, R.S, Christensen, E.I, Ioannou, Y.A, Krogh, T.N, Karpf, D.M, Nielsen, H.M

“…Abstract Introduction Recombinant activated factor VII (rFVIIa, NovoSeven®) is injected intravenously for the treatment of haemophilia patients with inhibitory…”
Get full text

Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8‐GP) and development of a human pharmacokinetic prediction model by Rode, F., Almholt, K., Petersen, M., Kreilgaard, M., Kjalke, M., Karpf, D. M., Groth, A. V., Johansen, P. B., Larsen, L. F., Loftager, M., Haaning, J.

“…Essentials N8‐GP is an extended half‐life recombinant factor VIII (FVIII) for the treatment of hemophilia A. Subcutaneous (SC) FVIII dosing might reduce the…”
Get full text

Factor VIII with a 237 amino acid B‐domain has an extended half‐life in F8‐knockout mice by Bloem, E., Karpf, D. M., Nørby, P. L., Johansen, P. B., Loftager, M., Rahbek‐Nielsen, H., Petersen, H. H., Blouse, G. E., Thim, L., Kjalke, M., Bolt, G.

“…Essentials Factor (F)VIII with an intermediate‐length B‐domain showed higher levels in murine gene therapy. FVIII with different B‐domain lengths were…”
Get full text

Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice by ELM, T., KARPF, D. M., ØVLISEN, K., PELZER, H., EZBAN, M., KJALKE, M., TRANHOLM, M.

“…N8 is a new recombinant factor VIII (rFVIII) compound produced and formulated without human‐ or animal‐derived protein. The aims of the present studies were to…”
Get full text

Hyperglycosylation prolongs the circulation of coagulation factor IX by BOLT, G., BJELKE, J. R., HERMIT, M. B., HANSEN, L., KARPF, D. M., KRISTENSEN, C.

Get full text

High‐affinity von Willebrand factor binding does not affect the anatomical or hepatocellular distribution of factor VIII in rats by Øie, C. I., Roepstorff, K., Behrens, C., Bøggild Kristensen, J., Karpf, D. M., Bolt, G., Gudme, C. N., Kjalke, M., Smedsrød, B., Appa, R. S.

“…Essentials Von Willebrand factor (VWF) stabilizes factor VIII (FVIII) and prevents its premature clearance. Rat anatomical and hepatocellular distribution…”
Get full text

Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs by KARPF, D. M., KJALKE, M., THIM, L., AGERSØ, H., MERRICKS, E. P., DEFRIESS, N., NICHOLS, T. C., EZBAN, M.

“…N8, a new recombinant factor VIII (rFVIII) compound developed for the treatment of haemophilia A, is produced in Chinese hamster ovary (CHO) cells and…”
Get full text

Effect of ketoprofen and its enantiomers on the renal disposition of methotrexate in the isolated perfused rat kidney by Karpf, D. M., Kirkegaard, A. L., Evans, A. M., Nation, R. L., Hayball, P. J., Milne, R. W.

“…ABSTRACT Non‐steroidal anti‐inflammatory drugs (NSAIDs) have been shown to inhibit the renal tubular secretion of methotrexate. However, the relative…”
Get full text

Perinatal complications and long-term neurodevelopmental outcome of infants with intrauterine growth restriction by von Beckerath, Anne-Karen, Kollmann, Martina, MD, Rotky-Fast, Christa, MD, Karpf, Eva, MD, Lang, Uwe, MD, PhD, Klaritsch, Philipp, MD

“…Objective The objective of the study was to evaluate perinatal and long-term complications of fetuses with intrauterine growth restriction (IUGR) compared with…”
Get full text

Clinical studies with oral lipid based formulations of poorly soluble compounds by Fatouros, Dimitrios G, Karpf, Ditte M, Nielsen, Flemming S, Mullertz, Anette

“…This work is an attempt to give an overview of the clinical data available on lipid based formulations. Lipid and surfactant based formulations are recognized…”
Get full text

Targeted enrichment sequencing in two midterm pregnancies with severe abnormalities on ultrasound by Kroisel, Peter Michael, MD, Häusler, Martin, MD, Klaritsch, Philipp, MD, Karpf, Eva, MD, Zebedin, Doris, MD, Tiran, Beate, MD, Pertl, Barbara, MD, Wagner, Klaus, Dr

“…A 29-year-old woman, with a history of medically justified termination for severe fetal anomalies at 23 weeks' gestation in 2014 and a miscarriage at 9 weeks'…”
Get full text

Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats by Karpf, Ditte M, Holm, René, Kristensen, Henning G, Müllertz, Anette

“…To compare the lymphatic transport and the portal absorption of halofantrine (Hf) when administered in (i) a triacylglycerol (TG) solution, (ii) an…”
Get full text

Effect of different surfactants in biorelevant medium on the secretion of a lipophilic compound in lipoproteins using Caco-2 cell culture by Karpf, Ditte M, Holm, René, Garafalo, Carole, Levy, Emile, Jacobsen, Jette, Müllertz, Anette

“…The impact of a pharmaceutical relevant metabolizable, ionic surfactant or two synthetic, nonionic surfactants on the absorption and lipoprotein incorporation…”
Get more information